• 

  

  • Basic Biology Dept.
  • Shinya Yamanaka
  • Yoshinori Yoshida
  • Masato Nakagawa
  • Keisuke Okita
  • Kazutoshi Takahashi
  • Takuya Yamamoto

  

  

  • Differentiation Induction Dept.
  • Junya Toguchida
  • Jun Takahashi
  • Jun K. Yamashita
  • Hidetoshi Sakurai

  

  

  • Clinical Applications Dept.
  • Tatsutoshi Nakahata
  • Taira Maekawa
  • Yasuhiro Yamada
  • Haruhisa Inoue
  • Kenji Osafune

  

  

  • Core Facilities Dept.
  • Ryuzo Torii
  • Yasuhiro Yamada
  • Takashi Aoi
  • Isao Asaka

  
• 
• 
• 
• 

• Research Overview
• Principal Investigator
• Publications
• Members

Research Overview

We are performing basic studies with the goal of developing cell, regenerative, and cancer molecular targeting therapies. Aiming at cell processing to prepare and supply quality-assured human cells for treatment necessary for the development of advanced cell and regenerative therapies, the Center for Cell and Molecular Therapy (CCMT) was founded opened in October 2002, and cooperates with the Graduate School of Medicine, University Hospital, and Institute for Frontier Medical Sciences to develop new cellular and regenerative therapies, such as the development promotion of pancreatic islet transplantation for severe diabetes and regenerative medicine for osteonecrotic diseases. To clinically apply iPS cells to clinical settings in the future, clinical studies using qualified clinical grade iPS cells and differentiation-induced cells should be manufactured in well-controlled cell processing center under current good manufacturing practices (cGMP). Manufacturers and scientists should be keenly aware that poor cGMP conditions can ultimately pose lifethreatening health risks to patients. Academic researchers, clinician-investigators(or physician scientists), and technicians should understand the importance of cell processing They together play a pivotal role in establishing cGMP cell processing with ensured safety and quality for cellular products. are mandatory necessary, as in studies on cell and regenerative therapies. Completion Establishment of the infrastructure including regulation for the development of novel cellular therapies is another major task. In addition, we are also performing translational research concerning cancer molecular targeting therapy aiming at the clinical application of basic studies. For example, we are earnestly promoting studies concerning the development of advanced treatment strategies methods, such as a novel tyrosine kinase inhibitor, named bafetinib (INNO-406) for the treatment of imatinib-resistant chronic myelogenous leukemia (clinical trial study currently underway), novel molecular targeting therapy including cancer therapy with siRNA (small interfering RNA), therapy targeting niches of for cancer stem cells niche, and immunotherapy using γδT cells.

Novel tyrosine kinase inhibitor Novel tyrosine kinase inhibitor, INNO-406 (Bafetinib) Potential effect on imatinib resistance leukemia is under investigation.